Tag: Pulmonary fibrosis

While the incidence of drug-induced lung injuries is reportedly rising, it remains a rare but severe side effect of certain therapies. This article explores **what medications cause lung scarring**, covering the drug classes involved, mechanisms of damage, and how this serious condition is managed.

While there is currently no cure for idiopathic pulmonary fibrosis (IPF), standard inhalers like bronchodilators do not treat the underlying scarring that characterizes the disease. The question, 'are inhalers good for pulmonary fibrosis?' has a nuanced answer, as their benefit depends on the specific circumstances and goals of treatment.

Metformin, a first-line medication for type 2 diabetes, is currently used by an estimated 20 million people in the U.S. alone, but its potential benefits beyond blood sugar control are increasingly under investigation. Amidst this expanding research, one key question has emerged from the medical community: **Does metformin help your lungs?**

In severe inflammatory lung conditions, corticosteroids like prednisone are powerful immunosuppressants used to calm the body’s exaggerated immune response. So, what does prednisone do to your lungs? It works by reducing the inflammation and swelling that can constrict airways and impair normal respiratory function.

While severe COVID-19 disease is a recognized cause of pulmonary fibrosis, evidence does not suggest a causal link between the antiviral drug remdesivir and this condition. In fact, some studies indicate that remdesivir may have a protective effect against the lung scarring caused by severe viral infections. This article explores the current scientific understanding of remdesivir's effects on the lungs.

Clinical studies and post-marketing surveillance show that while most patients can manage the adverse events of nintedanib, the most common is diarrhea, reported in a significant portion of patients. This often-reported side effect and others raise the important question, is nintedanib well tolerated?

According to Health Affairs, current definitions for specialty drugs lack consistency, but many share common traits, such as high cost, complex administration, and specialized handling. For patients and providers, the classification of **OFEV a specialty drug** is critical, as it dictates everything from dispensing procedures to insurance coverage and support programs. This designation reflects the medication's high cost and complex nature, requiring a specific distribution model and extensive patient support.

With over 380 medications known to cause respiratory adverse effects, it is a critical topic for patients and healthcare providers. Understanding what drugs can cause lung damage is the first step toward prompt identification and management of potentially serious drug-induced lung injury (DILI).

Clinical trials, such as the open-label extension of the INPULSIS trials (INPULSIS-ON), have shown that the efficacy of nintedanib in slowing idiopathic pulmonary fibrosis (IPF) progression can be sustained over the long term, with some patients treated for up to 68 months. This evidence confirms that for chronic and progressive conditions, the answer to "how long should I take nintedanib?" is often for an extended period, potentially indefinitely.

Idiopathic pulmonary fibrosis (IPF) affects 13 to 20 per 100,000 people worldwide [1.10.1, 1.10.5]. For those diagnosed, a key question is: is nintedanib long term use a viable strategy? The evidence points to yes, as it is designed for chronic disease management.